Market Herald logo


Be the first with the news that moves the market

Food Revolution Group has received its first Juice Lab product purchase from Metcash distribution.

FOD is an Australian company which operates fruit and vegetable processing facilities, manufacturing a range of high-quality juices, fibres, infused fruits, and waters. Its products include the absence of added sugars, concentrates, artificial colours and flavours, and preservatives.

Juice Lab products will now be available in Victorian IGA and Foodworks supermarkets. This will grow onto its already expanding consumer base of Woolworths, Aldi, Coles and other outlets.

Metcash is multi-million dollar Australian wholesale distributor and marketing company. It has nearly 1,700 supermarket retail stores across Australia as well as 2,700 liquor stores and 700 hardware stores.

In April 2019 an agreement was reached with ICC Global to see $8 million worth of FOD products delivered to China. With this sale FOD will upgrade its Victorian processing facility to keep up with growing Chinese consumers.

Over 1,260 square kilometres of new workspace will be added and new equipment such as gel and liquid sachet machines to help manufacture the products. These upgrades will allow for the introduction of new high-volume products such as fish proteins and health and beauty aids which will also be sold in China.

FOD Chief Executive John Florey believes the launch in Victoria will pave the way for more domestic orders.

“While our recent efforts have been on extending our distribution in China and other international markets, we are continuing to work to grow availability of our products in Australia as well which underpins our business and provides a solid platform to expand into China, he said.

Please see the ASX announcement for further details  

FOD by the numbers
More From The Market Herald
Incannex Healthcare (ASX:IHL)

" Incannex Healthcare (ASX:IHL) engages Procaps to manufacture sleep apnoea treatment

Incannex Healthcare (IHL) has engaged a company to manufacture its soft-gel capsules in preparation for upcoming clinical trials.
ISX (ASX:ISX) - Managing Director, John Karantzis

" iSignthis (ASX:ISX) completes demerger

Software company iSignthis (ISX) has completed the demerger of its European business ISC Financial EU (ISXFEU).

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.